An approach to antiretroviral treatment of HIV disease. Individualized therapy: the role of viral-burden measures.
Surrogate markers such as the CD4 lymphocyte count and viral p24 antigen level have now been joined by assays of HIV nucleic acid in patients' plasma as a measure of viral burden. The findings are already assisting in the development and clinical testing of antiretroviral agents. They also may facilitate therapeutic decision making for the individual patient.
Thompson
M A
MA
AIDS Research Consortium of Atlanta, USA.
D000998:Antiviral Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D018791:CD4 Lymphocyte Count; D016655:HIV Core Protein p24 / Q000097:blood; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000821:virology*; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans; D015203:Reproducibility of Results
D000998:Antiviral Agents; D015415:Biomarkers; D016655:HIV Core Protein p24